Convatec Group (LSE:CTEC) told investors on 18 Nov 2026 that it now expects FY26 Group organic Revenue growth of 6.25–7.0%, up from its previous range of 5.5–6.5%. The upgrade came in the company's "Convatec 10-month trading update", which also showed year-to-date organic revenue growth of 6.6% excluding InnovaMatrix, its skin-substitute product. Including InnovaMatrix, organic growth was 3.7%, and reported revenue growth was 4.8%.
The market responded quickly. Alongside the higher growth range, Convatec reiterated its profitability and Earnings targets and said its share buyback was on track.
The latest announcement
The update covers trading for the first 10 months of the financial year. According to the company's announcement, momentum strengthened in the second half. Two areas stood out:
- Infusion Care grew at a double-digit rate.
- Continence Care grew at a mid-to-high single-digit rate.
- InnovaMatrix, by contrast, continued to weigh on group growth and is expected to generate FY26 revenue of c.$5m.
The headline change was the guidance upgrade. Moving the organic growth range to 6.25–7.0% from 5.5–6.5% lifts both the bottom and the top of the range, which suggests management has more confidence in the remainder of the year than it had when the earlier guidance was set.
Convatec (LSE:CTEC) also reiterated that it expects an adjusted Operating Margin of at least 23%. That figure already absorbs a c.65bps foreign exchange headwind and a c.90bps drag from InnovaMatrix. In addition, the company said it continues to expect double-digit adjusted EPS growth.
The Business at a glance
Convatec's trading update highlights several product areas, including Infusion Care, Continence Care and InnovaMatrix. The year-to-date numbers show how much difference one product line can make to the overall picture. On an organic basis, growth was 6.6% without InnovaMatrix but 3.7% with it, a gap that reflects changes in the US market for skin substitutes.
The company has published a series of statements on that subject. Its press-release page lists releases dated 3 Nov 2025, 16 Dec 2025 and 29 Dec 2025 relating to US Medicare coverage and payment changes for skin substitutes. It has also issued a release on the Medicare competitive bidding programme, dated 1 Dec 2025. Their titles show that US reimbursement policy has been a recurring theme for the group.
Excluding that product, the update describes a business whose core franchises have gathered pace. Double-digit growth in Infusion Care and mid-to-high single-digit growth in Continence Care point to broad support for the raised guidance, rather than reliance on a single area.
Financial position and Capital allocation
Convatec provided a set of financial expectations for the year alongside its revenue guidance. According to the company's announcement:
- Total FY26 capex is expected at the upper end of $200–230m, with growth capex of $135–165m.
- Adjusted net finance expense is expected at c.$75m.
- Capital cash conversion is expected at c.90%.
- The c.$200m share buyback is on track.
The capex guidance at the upper end of its range indicates Convatec Group (LSE:CTEC) is continuing to invest for future growth, with growth capex making up a large share of the total. The buyback is a separate call on cash, and the company's website carries a dedicated "2026 Share buyback" investor page.
On funding, Convatec announced on 8 Oct 2025 the closing of "$500 million 5.300% senior notes due 2035", according to a press-release title on its website.
What to watch next
When those results arrive, investors are likely to focus on several points:
- Whether organic growth lands within the new 6.25–7.0% range.
- Whether the adjusted operating margin meets the target of at least 23%.
- Progress on the c.$200m share buyback and the level of cash conversion.
- Any further update on US reimbursement for skin substitutes and on InnovaMatrix revenue.
Any fresh statements from the company on Medicare coverage or payment policy would also be relevant, given the effect InnovaMatrix has had on group growth this year.
The bottom line
Convatec's 10-month trading update delivered a clear message: the group now expects FY26 organic revenue growth of 6.25–7.0%, ahead of its previous 5.5–6.5% range, supported by firmer momentum in Infusion Care and Continence Care in the second half. It reiterated its margin and earnings targets and said its buyback was on track, and the shares rose 9.4% on 18 Nov 2026. Against that, InnovaMatrix and US reimbursement policy remain a drag, currency is a headwind, and the company still has to deliver on its higher targets. The full-year results will show whether the upgraded guidance has been met.






Please wait processing your request...